Lupin Manufacturing Solutions (LMS), a subsidiary of pharma giant Lupin Limited, has entered into a long-term strategic alliance with PolyPeptide Group AG, a global CDMO known for its expertise in peptide-based active pharmaceutical ingredients (APIs). The collaboration is designed to boost supply chain resilience, improve operational efficiency, and prepare both companies for the fast-growing global peptides market.
The partnership will play a key role in advancing next-generation peptide therapeutics, including cutting-edge treatments in metabolic disorders—a segment witnessing rapid global demand. With this move, both organisations aim to position themselves strongly in the expanding peptide ecosystem.
Under this alliance, LMS and PolyPeptide will jointly focus on expanding sourcing capabilities, strengthening global peptide API supply chains, and integrating procurement and supply planning to ensure seamless operations. Both companies also emphasized their commitment to maintaining consistent product quality and reliable delivery standards worldwide.
Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, stated, “We are delighted to announce our strategic alliance with PolyPeptide. As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialised materials that support large-scale commercial production. This underscores our mission to establish secure, agile, and future-ready supply pathways for innovators worldwide.